Advanced in Histiocytosis
Advanced in Histiocytosis
161 Fort Washington Avenue, 
New York, NY 

Overview

Justine Kahn is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Kahn is rated as an Advanced provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 37 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 11 clinical trials in the study of Histiocytosis.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

161 Fort Washington Avenue, New York, NY 10032

Additional Areas of Focus

Dr. Kahn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


37 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
View 31 Less Clinical Trials
Similar Doctors
Distinguished in Histiocytosis
Pediatric Hematology Oncology
Distinguished in Histiocytosis
Pediatric Hematology Oncology
211 Clinton St, Apt 2c, 
Brooklyn, NY 
 (10.8 miles away)
Languages Spoken:
English

Nitya Gulati is a Pediatric Hematologist Oncology provider in Brooklyn, New York. Dr. Gulati is rated as an Advanced provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Primary Mediastinal B-Cell Lymphoma (PMBCL).

Distinguished in Histiocytosis
Pediatric Hematology Oncology
Distinguished in Histiocytosis
Pediatric Hematology Oncology
1275 York Ave, 
New York, NY 
 (5.3 miles away)
Languages Spoken:
English

Ira Dunkel is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Dunkel is rated as an Elite provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Retinoblastoma, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Brain Stem Cancer.

Advanced in Histiocytosis
Pediatric Hematology Oncology
Advanced in Histiocytosis
Pediatric Hematology Oncology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (0.1 miles away)
Languages Spoken:
English

Prakash Satwani is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Satwani is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Graft Versus Host Disease (GvHD), Anemia, Sickle Cell Disease, Hemoglobinopathy, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kahn's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile